Levosimendan reverted severe pulmonary hypertension in one patient on waiting list for heart transplantation.

[1]  J. Thayer,et al.  Heart rate variability, overnight urinary norepinephrine, and plasma cholesterol in apparently healthy human adults. , 2013, International journal of cardiology.

[2]  G. Parati,et al.  Intermittent Levosimendan Infusions in Advanced Heart Failure: Favourable Effects on Left Ventricular Function, Neurohormonal Balance, and One-Year Survival , 2012, Journal of cardiovascular pharmacology.

[3]  R. Benza,et al.  World Health Organization Pulmonary Hypertension group 2: pulmonary hypertension due to left heart disease in the adult--a summary statement from the Pulmonary Hypertension Council of the International Society for Heart and Lung Transplantation. , 2012, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[4]  A. Parkhomenko,et al.  Levosimendan: molecular mechanisms and clinical implications: consensus of experts on the mechanisms of action of levosimendan. , 2012, International journal of cardiology.

[5]  W. Buurman,et al.  Exploring the link between inflammation and the vagus nerve , 2010, Journal of internal medicine.

[6]  J. Thayer,et al.  Heart rate variability, overnight urinary norepinephrine and C‐reactive protein: evidence for the cholinergic anti‐inflammatory pathway in healthy human adults , 2009, Journal of internal medicine.

[7]  A. Cohen-Solal,et al.  Levosimendan vs. dobutamine: outcomes for acute heart failure patients on β‐blockers in SURVIVE † , 2009, European journal of heart failure.